<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01132378</url>
  </required_header>
  <id_info>
    <org_study_id>06-01-01</org_study_id>
    <nct_id>NCT01132378</nct_id>
  </id_info>
  <brief_title>Midvastus Versus Medial Parapatellar Approach for Minimally Invasive Total Knee Arthroplasty</brief_title>
  <official_title>Mini-midvastus vs. Medial Parapatellar Approach for Minimally Invasive Total Knee Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heekin Orthopedic Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stryker Orthopaedics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Heekin Orthopedic Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare two different surgical approaches for total knee
      replacement surgery. The mini-midvastus approach involves cutting less of the thigh muscle
      (quadriceps) tendon than the classic approach (median parapatellar) in order to implant the
      knee components. Both will have the same skin incision.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Knee Society Score</measure>
    <time_frame>2 year</time_frame>
    <description>The higher the score the better is the result (0-100). The knee society score reflects the outcomes and perception of the patients regarding function and pain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quadriceps Strength</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Mini-midvastus approach</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mini Midvastus approach with skin incision less than 13 cm long and vastus medialis obliquus dissection not more than 3 cm from the patellar margin was used to perform total knee arthroplasty in 40 patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medial Parapatellar Approach</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mini Medial Parapatellar approach with skin incision less than 13 cm. The extension into quadriceps tendon did not exceed 3 cm.Mini medial parapatellar approach was used to perform total knee arthroplasty.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Total knee arthroplasty</intervention_name>
    <description>staged bilateral total knee arthroplasty (not more than 7 days between surgeries)</description>
    <arm_group_label>Mini-midvastus approach</arm_group_label>
    <arm_group_label>Medial Parapatellar Approach</arm_group_label>
    <other_name>Stryker Triathlon posterior stabilized components</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient is a male or non-pregnant female between the ages of 21-80.

          2. Patient requires cemented primary total knee replacement.

          3. Patient has a diagnosis of osteoarthritis (OA), traumatic arthritis (TA) or avascular
             necrosis (AVN).

          4. Patient has intact collateral ligaments.

          5. Patient has signed and dated an IRB approved study specific consent form.

          6. Patient is able and willing to participate in the study according to the protocol for
             the full length of the expected term of follow-up, and to follow their physician's
             directions.

          7. Patient has failed to respond to conservative treatment modalities.

        Exclusion Criteria:

          1. Patient has had a prior procedure of high tibial osteotomy, cruciate ligament
             reconstruction or patellectomy of the surgical knee.

          2. Patient is morbidly obese, &gt;60% over ideal body weight for frame and height.

          3. Patient has a deformity at the involved knee greater than 45 degrees of flexion, 45
             degrees of varus or 45 degrees of valgus.

          4. Patient has an active or suspected latent infection in or about the knee joint.

          5. Patient has a malignancy in the area of the involved knee joint.

          6. Patient has a diagnosed systemic disease that would affect the subject's welfare or
             overall outcome of the study (i.e. moderate to severe osteoporosis, Paget's disease)
             or is immunologically suppressed, or receiving steroids in excess of physiologic dose
             requirements.

          7. Patient has a neurological deficit, which interferes with the patient's ability to
             limit weight bearing or places an extreme load on the implant during the healing
             period.

          8. Female patient is or plans to become pregnant during the course of the study.

          9. Patient has a known sensitivity to device materials.

         10. Patient has prior diagnosis of diabetic or peripheral neuropathy in operative
             extremity or other neurologic disease affecting limb strength

         11. Patient's bone stock is compromised by disease or infection, which cannot provide
             adequate support and/or fixation to the prosthesis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>R. David Heekin, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heekin Institute for Orthopedic Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Heekin Orthopedic Specialists</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 26, 2010</study_first_submitted>
  <study_first_submitted_qc>May 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2010</study_first_posted>
  <results_first_submitted>March 19, 2013</results_first_submitted>
  <results_first_submitted_qc>September 16, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 19, 2013</results_first_posted>
  <last_update_submitted>December 16, 2013</last_update_submitted>
  <last_update_submitted_qc>December 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Heekin Orthopedic Research Institute</investigator_affiliation>
    <investigator_full_name>R. David Heekin</investigator_full_name>
    <investigator_title>R. David Heekin, M.D.</investigator_title>
  </responsible_party>
  <keyword>Total knee arthroplasty</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Forty consecutive patients who underwent staged bilateral TKA (within no more than 7 days)were assessed at 2,6, 12 weeks and 6,12, and24 months postoperatively</recruitment_details>
      <pre_assignment_details>Forty consecutive patients who underwent staged bilateral Total Knee Arthroplasty were prospectively randomised to receive mini MedialParapatellar Approach in one knee and mini-midvastus approach in the other knee (left or right)within no more than 7 days.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Mini-midvastus Incision</title>
          <description>Total knee arthroplasty : staged bilateral total knee arthroplasty
Forty consecutive patients who underwent staged bilateral Total Knee Arthroplasty were prospectively randomised to receive mini-midvastus approach in one knee and mini-Medial Parapatellar Approachthe in another knee (left or right)within no more than 7 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Forty consecutive patients who underwent staged bilateral Total Knee Arthroplasty were prospectively randomised to receive mini MedialParapatellar Approach in one knee and mini-midvastus approach in the other knee (left or right)within no more than 7 days.</population>
      <group_list>
        <group group_id="B1">
          <title>Median Parepatellar Approach or Minimidvastus Approach</title>
          <description>Total knee arthroplasty : staged bilateral total knee arthroplasty</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.13" spread="6.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Knee Society Score</title>
        <description>The higher the score the better is the result (0-100). The knee society score reflects the outcomes and perception of the patients regarding function and pain</description>
        <time_frame>2 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Medial Parapatellar Approach</title>
            <description>Forty consecutive patients who underwent staged bilateral Total Knee Arthroplasty were prospectively randomised to receive mini MedialParapatellar Approach in one knee and mini-midvastus approach in the other knee (left or right)within no more than 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Mini-midvastus Approach</title>
            <description>Total knee arthroplasty : staged bilateral total knee arthroplasty</description>
          </group>
        </group_list>
        <measure>
          <title>Knee Society Score</title>
          <description>The higher the score the better is the result (0-100). The knee society score reflects the outcomes and perception of the patients regarding function and pain</description>
          <units>score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.70" spread="2.32"/>
                    <measurement group_id="O2" value="99.03" spread="1.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quadriceps Strength</title>
        <time_frame>2 year</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Midvastus or Medial Parapatellar Approach</title>
          <description>Forty consecutive patients who underwent staged bilateral Total Knee Arthroplasty were prospectively randomised to receive mini MedialParapatellar Approach in one knee and mini-midvastus approach in the other knee (left or right)within no more than 7 days.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The strength of the study is the standardized surgical protocol performed by a single surgeon and a prospectively randomized consecutive and blinded subjects</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>R. David Heekin MD, FACS</name_or_title>
      <organization>Heekin Institute for Orthopaedic Research</organization>
      <phone>904-634-0640</phone>
      <email>drheekin@heekinortho.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

